AstraZeneca Beats Q1 Profit Estimates and Issues Warning

ASTRAZENECA PLC beat first-quarter profit estimates on Wednesday midday, reporting core EPS of $2.58 on $15.29 billion in revenue. The results surpassed analyst expectations of $2.54 per share and $14.9 billion in sales, driven by 16% growth in oncology. Investors are weighing this operational strength against warnings that United States pricing policies could delay global drug launches.

Operational Strength vs. Policy Headwinds